linjc16/ctgov huggingface dataset:
Barriers for the Uptake of LaparoScopic Hysterectomy

Study Overview
=================
Brief Summary
-----------------
Hysterectomy (surgical removal of the uterus) is the most common major gynaecological operation in women in developed countries. In Queensland, 6000 women require a hysterectomy for irregular periods, benign tumours or pelvic pain every year. Surgical approaches to surgical removal of the uterus (womb) include Laparoscopic Hysterectomy (LH), Vaginal Hysterectomy (VH) and Abdominal Hysterectomy through an abdominal incision (AH). It is widely accepted that LH and VH are less invasive surgical procedures, cause less bleeding, surgical complications and pain and are associated with quicker recovery from surgery than the more invasive AH. In a clinical trial comparing LH and AH we recently demonstrated that LH outperforms AH with regards to cost effectiveness causing less total health-services cost than AH. Implementation of LH in Queensland could save $9.8 million every year. Despite the evidence for LH and VH, 2600 hysterectomies (43%) are still performed through an open, abdominal incision. In brief, a common but outdated operation is still performed regularly causing not only unnecessary pain, surgical adverse events and longer hospital stay but also increased healthcare costs. This study will assess reasons why a significant number of gynaecologists and patients prefer AH over LH (Barriers to the uptake of laparoscopic hysterectomy). We will survey specialist gynaecologists as well as patients who have had a hysterectomy for different health reasons. Based on the information from the survey the investigators will develop an intervention to increase the rate of laparoscopic hysterectomies in Queensland and pilot test it.

Official Title
-----------------
What Would it Take to Reduce the Proportion of Women Who Have a Hysterectomy Via an Open Abdominal Approach in Australia?

Conditions
-----------------
Hysterectomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obstetricians and Gynaecologists or Women who have had a hysterectomy in the previous 2 years Exclusion Criteria: Women who have had a hysterectomy more than 2 years ago Women who had a hysterectomy for cancerous conditions
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Consumers<br>Women who have had a Hysterectomy in the previous 2 years | |
| Doctors<br>Obstetricians and Gynaecologists | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire will identify barriers |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
total abdominal hysterectomy, total laparoscopic hysterectomy, vaginal hysterectomy
Role of ASICs in Human Inflammatory Pain

Study Overview
=================
Brief Summary
-----------------
In recent years, ion channels have emerged as new therapeutic targets for pain. Among these channels, ASICs (Acid Sensing Ion Channels) are of particular interest because they are directly activated by extracellular acidity, which is a major cause of pain. Indeed, many painful conditions such as ischemia, inflammation, tumor development or tissue incision are accompanied by tissue acidification. ASIC are excitatory ion channels that are expressed in neurons, including nociceptive sensory neurons. In humans, the use of amiloride, a nonspecific inhibitor of ASICs, has demonstrated their role in the perception of pain induced by subcutaneous injections of acidic solutions. ASICs thus appear as new candidates capable of mediating pain in humans. A growing number of data suggests that, in addition to protons, ASICs may also be activated by one or more endogenous compounds produced during inflammation. The purpose of this research project is to identify these compounds by testing the effects of human inflammatory exudates on ASICs activity. The discovery of such compounds would definitely validate ASICs as novel therapeutic targets for pain treatment in humans

Official Title
-----------------
Study of the Role of Acid Sensing Ion Channels (ASICs) in Human Inflammatory Pain

Conditions
-----------------
Osteoarthritis, Arthritis, Chondrocalcinosis, Gouty Arthritis, Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: septic arthritis gonarthrosis in push-inflammatory microcrystalline arthropathies chronic inflammatory rheumatism Exclusion Criteria: refusal to participate in the protocol
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| arthritis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| activation or miodulation to Electrical potential of ionic channel in the synovial fluid | only once because it's an single ponction of sinovial fluid. | 1 day |
Evaluation of Tibial and Femoral Tunnel Position After Arthroscopic Reconstruction of the Anterior Cruciate Ligament

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the accuracy of tunnel positions in anterior cruciate ligament reconstruction

Detailed Description
-----------------
The tunnel placement in ACL reconstruction is the most important predictor of clinical outcome and there is a high rate of inaccurate tunnel placements, even when performed by experienced surgeons.Tibial and femoral tunnel positions are one of the major concerns in anterior cruciate ligament reconstruction which have a great impact on the final surgical results

Official Title
-----------------
Study of Evaluation of Tibial and Femoral Tunnel Position After ACL Reconstruction

Conditions
-----------------
Anterior Cruciate Ligament Rupture

Intervention / Treatment
-----------------
* Procedure: Anterior cruciate ligament reconstruction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: anterior cruciate ligament rupturing Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: determining correct tunnel positions<br> | Procedure: Anterior cruciate ligament reconstruction<br>* reconstruct the anterior cruciate ligament rupturing<br>* Other names: ACL reconstruction;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of correct femoral tunnel position | we evalauted femoral tunnel positions | 5 min after operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of correct Tibial tunnel position | we evalauted tibial tunnel position | 5 min after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arthroscopy, Anterior Cruciate Ligament, Tibial Tunnel.
Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine whether oral losartan is effective in the treatment of diabetic macular edema (DME) as an adjuvant for intravitreal bevacizumab (IVB).

Conditions
-----------------
Diabetic Macular Edema

Intervention / Treatment
-----------------
* Drug: Losartan
* Drug: Intravitreal bevacizumab
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All type 2 diabetes mellitus patients with clinically significant macular edema(CSME), except those mentioned as exclusion criteria Exclusion Criteria: Patients with Uncontrolled hypertension Patients with Proliferative diabetic retinopathy Patients Who received angiotensin converting enzyme inhibitor(ACEI) or angiotensin receptor blocker(ARB) Previous treatment for diabetic retinopathy (e.g., laser photocoagulation, photodynamic therapy, intravitreal injections of steroids, or anti-vascular endothelial growth factor, retinal surgery) media opacities evidence of any other ocular disease(e.g., glaucoma, uveitis, age related macular degeneration or etc.,) Pathologic myopia > 6 Diopter Patients with poor fixation or cooperation Patients with renal or cardiac disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Losartan<br>Oral losartan 50 mg daily for 6 months | Drug: Losartan<br> <br> Drug: Intravitreal bevacizumab<br> <br> * Other names: Avastin;|
| Placebo Comparator: Placebo<br>Oral placebo daily for 6 months | Drug: Intravitreal bevacizumab<br> <br> * Other names: Avastin;Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference in ETDRS best-corrected visual acuity (BCVA) between arms |  | Within 6 months from therapy | 
| Difference in frequency of intravitreal Bevacizumab injection between arms |  | Within 6 months from therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in central macular thickness(measured by spectral domain optical coherence tomography) |  | Within 6 months from therapy |
Visual Performance of Bilateral AcrySof ReSTOR Aspheric +4

Study Overview
=================
Brief Summary
-----------------
Determine the clinical visual outcomes following bilateral implantation of the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) and to demonstrate what percentage of the subjects obtain spectacle freedom.

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Device: AcrySof ReSTOR Aspheric +4


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with cataracts Exclusion Criteria: Preexisting conditions confounding results; > 1 Diopter preoperative astigmatism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ReSTOR +4<br>AcrySof ReSTOR Aspheric +4 | Device: AcrySof ReSTOR Aspheric +4<br>* Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contrast sensitivity, patient survey |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AcrySof ReSTOR Aspheric +4
The Factors Affecting ADR of Screening Colonoscopy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the impact of multilevel factors on the quality of screening colonoscopy, reflected mainly by adenoma detection rate (ADR).

Detailed Description
-----------------
The subjects will include patients who need to screening colonoscopies by 21 endoscopists between January 2019 and December 2019 were retrospectively enrolled in this unit. Multilevel factors, including patient-, proceduralist-, and procedure-level characteristics were analyzed for the relationship with ADR.

Official Title
-----------------
Comprehensive Analysis of Multilevel Factors Affecting Adenoma Detection Rates of Screening Colonoscopy

Conditions
-----------------
Adenoma Detection Rate, Colonoscopy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients were retrospectively included in this study if they had undergone a completed colonoscopy. Exclusion Criteria: prior colonoscopy within 3 years; medical history of inflammatory bowel disease (IBD), CRC, or abdominal surgery; fair or poor quality of bowel preparation (fair quality: some semisolid stool that could be suctioned or washed away but >90% of mucosal surface seen; poor quality: semisolid stool that could not be suctioned or washed away with <90% of mucosal surface seen); failure in cecal intubation; withdrawal time without removing<6 min.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenoma detection rate | the proportion of colonoscopies in which at least one adenoma was detected | After histopathologically examined, reviewed, and confirmed, an average of 7 days. |
The Clinical Significance of Biochemical 11 Deoxycortisol Levels

Study Overview
=================
Brief Summary
-----------------
data from charts regarding clinical characteristics and androgens levels from first to last visit were collected

Detailed Description
-----------------
data from charts regarding clinical characteristics and androgens levels from first to last visit were collected Female patients only ages 10-18 years who were referred to the combined gynecology endocrinology adolescents clinic

Official Title
-----------------
The Clinical Significance of Biochemical Polymorphism in the 11 Deoxycortisol Levels Before and After Stimulation With Adrenocorticotrofin

Conditions
-----------------
Retrospective

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 10-18 years referred to gynecology endocrinology adolescents clinic Exclusion Criteria: no data available in chart no blood work available

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of hyperandrogenism signs (1 to 3 categorized) | hirsuitism, acne, menses, each marked as 0 or 1 (none or present) | 3 years |
Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)

Study Overview
=================
Brief Summary
-----------------
PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest of molecular analysis on circulating tumor DNA in the follow-up of the disease.

Official Title
-----------------
Personalized Circulating DNA Follow-up in Melanoma

Conditions
-----------------
Melanoma

Intervention / Treatment
-----------------
* Procedure: Personalized Circulating DNA follow-up


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: locally advanced, operable melanoma treated by immunotherapy or anti-BRAF and anti-MEK targeted therapies (stage IIIb, IIIc) or exclusive immunotherapy (stage IV) in an adjuvant situation. Exclusion Criteria: second cancer woman who is pregnant, likely to be pregnant or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Personalized Circulating DNA follow-up<br>FFPE tissue sample + blood sample (20ml) | Procedure: Personalized Circulating DNA follow-up<br>* FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Studying the tumor molecular abnormalities resulting from circulating tumor DNA (ctDNA) to predict the resistance to treatment | Quantity of ctDNA / Resistance to treatment defined as a change in treatment decided during staff meeting | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Circulating tumour DNA, immunotherapy, targeted therapy
Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the appropriate regimen of GSK HRV vaccine for concomitant administration with EPI vaccines to infants in South Africa.

Official Title
-----------------
A Phase II, Randomized, Double-blind, Placebo-controlled Study of Safety, Reactogenicity and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine at 10E6.5 CCID50 Viral Concentration in Healthy Infants (Approximately 5-10 Weeks Old) in the Republic of South Africa

Conditions
-----------------
Infections, Rotavirus

Intervention / Treatment
-----------------
* Biological: HRV vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy infants born after a normal gestation period (>=36 weeks), between 5 and 10 weeks of age at Dose 1 with confirmed negative HIV status of the subject's mother. Written informed consent was obtained from the parent/guardian of the subject before study entry. Exclusion Criteria: History of allergic disease/polio disease, Confirmed or suspected immunosuppressive or immunodeficient condition, Clinically significant history of chronic gastrointestinal disease or other serious medical condition as determined by the investigator, Received treatment prohibited by the protocol. Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

Ages Eligible for Study
-----------------
Minimum Age: 5 Weeks
Maximum Age: 10 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: HRV vaccine|Two or three oral doses|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Seroconversion after HRV vaccination |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| shedding, serum anti-rota IgA antibody concentrations, anti-polio 1, 2 and 3 seroprotection rates, reactogenicity, safety |  |  |
Functional Outcomes and HRQoL in Upper-extremity Sarcoma Patients After Limb Salvage

Study Overview
=================
Brief Summary
-----------------
This study aims to assess the functional ability and health-related quality of life (HRQoL) of upper extremity sarcoma patients who have undergone limb salvage surgery.

Detailed Description
-----------------
The purpose of this study is to assess the functional capabilities and health-related quality of life (HRQoL) of upper-extremity sarcoma patients who have undergone limb salvage surgery. Patient hospital records are retrospectively reviewed for demographic and clinical data. The patient recruitment takes place at the outpatient clinic of the Comprehensive Cancer Center, Helsinki University Hospital, and Tampere University Hospital. The study includes a cross-sectional assessment at six months follow-up with five validated questionnaires. A follow-up is conducted two and five years after surgery in the outpatient clinic.

Official Title
-----------------
Functional Outcomes and Health Related Quality of Life in Upper-extremity Sarcoma Patients After Limb Salvage: a Prospective Study

Conditions
-----------------
Cancer of Muscle

Intervention / Treatment
-----------------
* Procedure: Limb salvage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Upper extremity soft tissue sarcoma locating in between scapula to arm No metastasis at the time of diagnosis Undergone limb salvage surgery A minimum of 6 months follow-up Written consent Age > 18 Exclusion Criteria: Age <18 No limb-salvage surgery due to sarcoma Deceased

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Limb salvage|Local or free flaps|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health-related quality of life and upper-extremity functional capability | To assess health-related quality of life and upper-extremity functional capability | 6 months to five years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sarcoma recurrence | to assess sarcoma recurrence | 6 months to five years | 
| Quality of Life Questionnaire-Core 30 | to assess the health-related quality of life | 6 months to five years | 
| the 15D health-related quality of life instrument | to assess the health-related quality of life | 6 months to five years | 
| The QuickDASH | to assess the upper-extremity function | 6 months to five years | 
| The MSTS upper extremity section | to assess the upper-extremity function | 6 months to five years | 
| The TESS upper extremity section | to assess the upper-extremity function | 6 months to five years |